What dose of BPC-157 and TB-500 have research studies actually used?

The rat Achilles tendon healing study that established BPC-157's musculoskeletal research profile used 10 microgram, 10 nanogram or 10 picogram per kg body weight, given intraperitoneally once daily (PMID 16583442). For TB-500's active molecule, thymosin beta-4, a Phase 1 trial of recombinant human thymosin beta-4 (NL005) gave healthy volunteers single intravenous doses from 0.05 to 25 microgram per kg, or repeated doses of 0.5 to 5 microgram per kg per day for 10 days, under clinical supervision (PMID 34346165). These are doses a specific trial administered, not a self-administration protocol: no published human dosing protocol exists for BPC-157, for TB-500, or for the combination.

What side effects have been documented for BPC-157 and TB-500 in published studies?

A multi-species preclinical toxicology programme covering mice, rats, rabbits and dogs found BPC-157 well tolerated with no serious toxicity; the notable systemic finding on repeated dosing was a reversible decrease in creatinine in dogs at 2 mg per kg that resolved after a two-week washout, alongside mild local irritation (PMID 32334036). In a Phase 1 trial of recombinant human thymosin beta-4 (NL005), TB-500's active molecule, adverse events were mild to moderate with no serious events or dose-limiting toxicities (PMID 34346165). A pig cardiac-surgery study reported that, in separate in-vitro assays using isolated arteries and blood at 0.1 to 1.0 mM, thymosin beta-4 produced vasoconstriction and reduced blood-clot firmness when combined with an antiplatelet drug (PMID 27199757). No adverse-event data exists for the two peptides administered together.

What is not yet known about the safety of combining BPC-157 and TB-500?

A 2025 narrative review found only three small human pilot studies of BPC-157 in total, covering intravenous safety, knee injections and interstitial cystitis, all uncontrolled, and concluded the peptide should still be considered investigational (PMID 40789979). Thymosin beta-4, the molecule sold as TB-500, also has a limited human record, though it includes healthy-volunteer, wound-healing, ophthalmic and post-heart-attack trials. No animal or human study has tested BPC-157 and TB-500 given together for combined safety or interaction, so the safety profile of the actual blend has never been formally assessed.

Has BPC-157 been tested for intravenous safety in humans?

Yes, in a small 2025 pilot study: two healthy adults received intravenous BPC-157 in escalating doses, 10 mg on day one and 20 mg on day two, with vital signs and blood biomarkers monitored for three days (PMID 40131143). No adverse effects were reported and heart, liver, kidney, thyroid and glucose markers were unaffected. Given the two-person sample this provides only an initial signal, and the authors said further studies were needed to confirm safety before any broader conclusion about human safety can be drawn.

Is there published clinical evidence for TB-500 (thymosin beta-4) in heart attack recovery?

Yes. A 2025 randomised, placebo-controlled, double-blind trial enrolled 96 patients after a STEMI heart attack and randomised them between recombinant human thymosin beta-4, the molecule sold in research form as TB-500, and placebo. The overall comparison was not statistically significant; a reduced infarcted area at 90-day follow-up was seen in the subgroup treated within 8 hours of reperfusion (PMID 41229390). This is clinical-grade recombinant thymosin beta-4 administered under a registered trial protocol, not the research-use TB-500 sold for laboratory use, and it has not led to any regulatory approval. It is nonetheless the strongest published human evidence for either peptide in this stack.

Is there published human evidence for TB-500 (thymosin beta-4) outside of cardiac research?

Yes. A Phase 2 randomised, placebo-controlled trial of thymosin beta-4 eye drops in nine patients with severe dry eye reported significant reductions in ocular discomfort and in corneal fluorescein staining by day 56 (PMID 25826322). This supports a local ocular-surface repair activity of full-length thymosin beta-4, distinct from the cardiac studies already mentioned in this article. The trial used a topical eye-drop formulation, not the injectable research peptide sold here, so the finding is evidence about the molecule's biology, not a use case for this product.

What did the original BPC-157 Achilles tendon study find?

In rats with a detached Achilles tendon, animals treated with BPC-157 showed better functional, biomechanical and histological healing than untreated controls, measured from day 1 through day 21 after surgery, at doses of 10 microgram, 10 nanogram or 10 picogram per kg (PMID 16583442). BPC-157 also counteracted the healing delay caused by corticosteroid treatment in the same model. This is the animal study most often cited for BPC-157's tendon-repair research profile, and the one the article's dosing section references as 'Sikiric et al.'

Is there published research on BPC-157 and gastrointestinal protection?

Yes. In a rat model of gastric ulcer, BPC-157 reduced ulcer area and accelerated healing, with intramuscular administration proving more effective than intragastric dosing (PMID 15052688). This gastroprotective research is one of the original lines of evidence behind BPC-157, alongside its later tendon and ligament studies. All of this evidence comes from animal models; no controlled human trial of BPC-157 for gastrointestinal outcomes has been published.

Is there any published human research on BPC-157 and TB-500 used together?

The only published human data on the two peptides together comes from a retrospective case series of 17 patients receiving intra-articular knee injections, most of whom received BPC-157 alone while 4 received BPC-157 combined with TB-500; most patients across the series reported pain relief (PMID 34324435). No animal study and no controlled human trial has tested BPC-157 and TB-500 given together for interaction, safety or comparative efficacy. As the article's own Research Foundation section notes, the Wolverine Stack rationale rests on the two peptides' separate literatures, not on a dedicated co-administration study.

Are BPC-157 and TB-500 approved medicines in the EU?

No. Neither compound holds EMA or FDA approval as a drug for any human or veterinary indication, and neither appears in any approved medicines database. Both are sold and shipped strictly as research chemicals, not as medicines, and are not intended for human consumption. Thymosin beta-4, the molecule behind TB-500, has been tested in registered but still unapproved clinical trials; that has not led to a marketing approval anywhere.

Are BPC-157 and TB-500 prohibited substances under anti-doping rules?

Yes, for both. BPC-157 falls under the S0 Non-Approved Substances category of the WADA Prohibited List, banned at all times, in and out of competition. TB-500, the research name for thymosin beta-4, falls under WADA's S2 category for peptide hormones, growth factors and related substances, also prohibited at all times, and the NCAA's banned-substances list names both compounds directly.

Does BPC-157 or TB-500 show up on a standard drug test?

No. Standard workplace or medical drug panels screen for drugs of abuse such as THC, opioids, cocaine and amphetamines using immunoassay methods that do not include peptide hormones like BPC-157 or thymosin beta-4. Anti-doping testing is different: WADA-accredited laboratories run targeted mass-spectrometry panels built specifically to detect banned peptides, so an athlete under a WADA-code testing programme is tested for exactly these compounds.

How should the Wolverine Stack be reconstituted for laboratory use?

Because the two peptides are supplied pre-mixed in a single lyophilised vial, only one reconstitution step is needed instead of preparing BPC-157 and TB-500 separately. Add bacteriostatic water by letting it run slowly down the inside wall of the vial, then swirl gently rather than shaking, since vigorous agitation can cause foaming and may denature the peptide. This is laboratory handling guidance for preparing a research solution, not an instruction for human use.

How should the Wolverine Stack be stored before and after reconstitution?

Before reconstitution, store the lyophilised powder at -20 degC, where it remains stable for months. After reconstitution, refrigerate at 2-8 degC and use within 2-4 weeks. Both peptides are light-sensitive, so keep the vial in a dark container or otherwise protected from light at every stage.

Is TB-500 always the full-length thymosin beta-4 molecule?

Not automatically: the name TB-500 is used in the market both for the complete 43-amino-acid thymosin beta-4 protein and for a shorter synthetic fragment, Ac-LKKTETQ, which is a different and much smaller molecule. This is exactly why a Certificate of Analysis matters rather than trusting a vial label alone. In the Wolverine Stack, the COA confirms the full 43-amino-acid form, the same molecule studied in the cardiac and corneal research cited above, not the short fragment.

How can a specific Wolverine Stack batch's COA be verified?

Each batch is tested by Janoshik Analytical, a third-party lab, with separate HPLC purity and mass-spectrometry identity results for BPC-157 and TB-500 individually rather than one combined figure. The COA can be checked against the specific batch using the verification link at verify.janoshik.com. PeptidesDirect publishes the certificate as issued rather than running its own laboratory testing.

Buy Wolverine Stack: BPC-157 + TB-500 for Regeneration Research

The Wolverine Stack - the combination of BPC-157 and TB-500 - has established itself as one of the most discussed peptide pairings in preclinical regeneration research. The name alludes to the regenerative ability of the eponymous comic book character, and while that is of course an exaggeration, it reflects the core of the research hypothesis: two peptides that address tissue repair on multiple levels simultaneously through complementary signalling pathways.

WOLVERINE (BPC-157 + TB-500)regeneration

The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.

What Is the Wolverine Stack?

The Wolverine Stack is a pre-mixed blend of two peptides in a single vial:

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, originally derived from a protective protein found in human gastric juice. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val has been investigated in hundreds of preclinical studies - from tendon repair and gastrointestinal protection to bone healing.

TB-500 is, as supplied here, full-length synthetic Thymosin Beta-4 (Tb4) - the complete 43-amino-acid actin-sequestering peptide, the most abundant of its kind in eukaryotic cells (the Janoshik COA confirms this full 43-aa form). Note that in the market the name "TB-500" is also used for a short Ac-LKKTETQ fragment, which is exactly why a COA matters: the Janoshik COA certifies the full 43-aa Tb4. Because the supplied material is the complete molecule, the published Thymosin Beta-4 literature applies directly to it. Tb4 is responsible for cell migration, angiogenesis and inflammation modulation.

Why This Particular Combination?

The rationale behind the Wolverine Stack is based on the complementarity of the two peptides within the healing cascade:

BPC-157 acts primarily locally. It focuses on the immediate repair zone: upregulation of growth factors (VEGF, EGF), stimulation of collagen synthesis in fibroblasts, modulation of the NO system and activation of the FAK-paxillin signalling pathway for cell migration. Its effects on tendons and ligaments are particularly well documented.

TB-500 acts more systemically. It promotes actin reorganisation in cells throughout the entire organism, supports angiogenesis through mechanisms different from BPC-157 and modulates the inflammatory response on a broader level. TB-500 also facilitates the migration of stem cells and repair cells to damaged tissue.

Research Foundation

BPC-157: A systematic review by Vasireddi et al. published in 2025 confirms the potential for healing musculoskeletal injuries. A 2026 MDPI review in Pharmaceuticals extends the scope to complex joint injuries and describes the cytoprotective approach as a novel therapeutic perspective.

TB-500 / Thymosin Beta-4: Goldstein et al. documented the role of Thymosin Beta-4 in wound healing and cardiac regeneration. Studies show that Tb4 accelerates the healing of corneal injuries, improves cardiac function after ischaemia and promotes hair follicle stem cell migration.

The Combination: Although no formal clinical studies on the exact Wolverine Stack combination exist, the rationale is based on the complementarity of their mechanisms of action. BPC-157 addresses local repair mechanisms (tendons, ligaments, muscles), while TB-500 shows more systemic effects (cell migration, angiogenesis, inflammation modulation). The research hypothesis: the combination is not merely additive but potentially synergistic.

Mechanisms of Action Compared

Mechanism	BPC-157	TB-500
Angiogenesis	VEGF/EGF upregulation	Actin-mediated neovascularisation
Cell migration	FAK-paxillin pathway	Actin sequestration
Inflammation	JAK-2/STAT-3, NO modulation	Cytokine modulation
Primary focus	Local (tendons, GI tract)	Systemic (multiple tissues)
Collagen	Direct stimulation	Indirect via remodelling

Angiogenesis

BPC-157: VEGF/EGF upregulation
TB-500: Actin-mediated neovascularisation

Cell migration

BPC-157: FAK-paxillin pathway
TB-500: Actin sequestration

Inflammation

BPC-157: JAK-2/STAT-3, NO modulation
TB-500: Cytokine modulation

Primary focus

BPC-157: Local (tendons, GI tract)
TB-500: Systemic (multiple tissues)

Collagen

BPC-157: Direct stimulation
TB-500: Indirect via remodelling

This complementarity is why the combination is considered particularly promising in the research community.

Quality Criteria When Purchasing

For the Wolverine Stack, the quality of both peptide components is critical:

Separate HPLC analyses: The COA should report purity data for BPC-157 and TB-500 individually. An overall purity figure alone is insufficient.
Mass spectrometry: Identity confirmation for both peptides.
Purity ≥98%: For both components.
Independent testing: At PeptidesDirect, every batch of the Wolverine Stack is verified by Janoshik Analytical.

Amounts Used in the Research Literature

The amounts reported in the published research describe what specific studies administered in animal models, not a protocol for use in a person:

BPC-157: animal studies such as Sikiric et al. administered on the order of 10 ug/kg body weight, given to the animals in the study.
TB-500: the thymosin beta-4 doses cited in the trials on this page describe what those studies gave their subjects, not a human protocol.

The Wolverine Stack from PeptidesDirect contains 10 mg of each peptide in a single vial and is supplied strictly for laboratory research, not for administration to a person.

Storage

The Wolverine Stack is supplied as a lyophilised powder:

Before reconstitution: Store at -20 °C. Stable for months.
After reconstitution: Refrigerate at 2-8 °C. Use within 2-4 weeks.
Reconstitution: Use bacteriostatic water. Allow to run slowly down the vial wall, swirl gently.
Light protection: Both peptides are light-sensitive. Use dark vials or store protected from light.

Why Buy the Wolverine Stack from PeptidesDirect?

Janoshik-verified: Independent analytics for both components in every batch.
Pre-mixed: BPC-157 and TB-500 in one vial - no need for separate sourcing and mixing.
EU shipping: No customs, no import fees. Delivery in 2-3 business days with tracking.
Price: The Wolverine Stack 10 mg is available for EUR49.99 - more affordable than purchasing both peptides separately.

Frequently Asked Questions